You just read:

FDA Approves MAVENCLAD® (Cladribine) Tablets as First and Only Short-Course Oral Treatment for Relapsing-Remitting and Active Secondary Progressive Multiple Sclerosis

News provided by

EMD Serono

Mar 29, 2019, 19:55 ET